Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience
- PMID: 20096533
- DOI: 10.1016/j.jacc.2009.12.014
Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience
Abstract
Objectives: The aim of this study was: 1) to evaluate the acute and late outcomes of a transcatheter aortic valve implantation (TAVI) program including both the transfemoral (TF) and transapical (TA) approaches; and 2) to determine the results of TAVI in patients deemed inoperable because of either porcelain aorta or frailty.
Background: Very few data exist on the results of a comprehensive TAVI program including both TA and TF approaches for the treatment of severe aortic stenosis in patients at very high or prohibitive surgical risk.
Methods: Consecutive patients who underwent TAVI with the Edwards valve (Edwards Lifesciences, Inc., Irvine, California) between January 2005 and June 2009 in 6 Canadian centers were included.
Results: A total of 345 procedures (TF: 168, TA: 177) were performed in 339 patients. The predicted surgical mortality (Society of Thoracic Surgeons risk score) was 9.8 +/- 6.4%. The procedural success rate was 93.3%, and 30-day mortality was 10.4% (TF: 9.5%, TA: 11.3%). After a median follow-up of 8 months (25th to 75th interquartile range: 3 to 14 months) the mortality rate was 22.1%. The predictors of cumulative late mortality were peri-procedural sepsis (hazard ratio [HR]: 3.49, 95% confidence interval [CI]: 1.48 to 8.28) or need for hemodynamic support (HR: 2.58, 95% CI: 1.11 to 6), pulmonary hypertension (PH) (HR: 1.88, 95% CI: 1.17 to 3), chronic kidney disease (CKD) (HR: 2.30, 95% CI: 1.38 to 3.84), and chronic obstructive pulmonary disease (COPD) (HR: 1.75, 95% CI: 1.09 to 2.83). Patients with either porcelain aorta (18%) or frailty (25%) exhibited acute outcomes similar to the rest of the study population, and porcelain aorta patients tended to have a better survival rate at 1-year follow-up.
Conclusions: A TAVI program including both TF and TA approaches was associated with comparable mortality as predicted by surgical risk calculators for the treatment of patients at very high or prohibitive surgical risk, including porcelain aorta and frail patients. Baseline (PH, COPD, CKD) and peri-procedural (hemodynamic support, sepsis) factors but not the approach determined worse outcomes.
Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
A step forward in the evaluation of transcatheter aortic valve implantation.J Am Coll Cardiol. 2010 Mar 16;55(11):1091-2. doi: 10.1016/j.jacc.2010.01.007. J Am Coll Cardiol. 2010. PMID: 20137878 No abstract available.
-
Interventional cardiology: TAVI is effective for the treatment of high-risk patients.Nat Rev Cardiol. 2010 Jul;7(7):359. doi: 10.1038/nrcardio.2010.77. Nat Rev Cardiol. 2010. PMID: 21080574 No abstract available.
Similar articles
-
[POL-TAVI First--Polish report on transcatheter aortic valve implantation (TAVI) of Edwards-Sapien prosthesis in the first 19 high risk patients with severe aortic stenosis and comorbidities].Kardiol Pol. 2009 Aug;67(8):936-40. Kardiol Pol. 2009. PMID: 19784896 Polish.
-
Transapical versus transfemoral aortic valve implantation: a comparison of survival and safety.Ann Thorac Surg. 2011 Jan;91(1):57-63. doi: 10.1016/j.athoracsur.2010.07.072. Ann Thorac Surg. 2011. PMID: 21172486
-
Risk of acute kidney injury in patients with severe aortic valve stenosis undergoing transcatheter valve replacement.Nephrol Dial Transplant. 2009 Jul;24(7):2175-9. doi: 10.1093/ndt/gfp036. Epub 2009 Feb 11. Nephrol Dial Transplant. 2009. PMID: 19211648
-
Transcatheter aortic valve implantation: anesthetic considerations.Anesth Analg. 2009 May;108(5):1453-62. doi: 10.1213/ane.0b013e31819b07ce. Anesth Analg. 2009. PMID: 19372319 Review.
-
Transcatheter aortic valve implantation outcomes: implications for practice.J Cardiovasc Nurs. 2012 May-Jun;27(3):270-82. doi: 10.1097/JCN.0b013e318217d288. J Cardiovasc Nurs. 2012. PMID: 21760524 Review.
Cited by
-
Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based Analysis (part B).Ont Health Technol Assess Ser. 2012;12(14):1-62. Epub 2012 May 1. Ont Health Technol Assess Ser. 2012. PMID: 23074424 Free PMC article. Review.
-
Trans-catheter aortic valve replacement program in a community hospital - Comparison with US national data.PLoS One. 2018 Sep 27;13(9):e0204766. doi: 10.1371/journal.pone.0204766. eCollection 2018. PLoS One. 2018. PMID: 30261048 Free PMC article.
-
Diagnosis and Management of Rare Case of Mesenteric Hematoma Rupture after Transcatheter Aortic Valve Replacement (TAVR): A Case Report and Review of the Literature.Case Rep Vasc Med. 2018 Nov 21;2018:6273538. doi: 10.1155/2018/6273538. eCollection 2018. Case Rep Vasc Med. 2018. PMID: 30584489 Free PMC article.
-
Comparison of Early Clinical Results of Transcatheter versus Surgical Aortic Valve Replacement in Symptomatic High Risk Severe Aortic Stenosis Patients.Korean J Thorac Cardiovasc Surg. 2013 Oct;46(5):346-52. doi: 10.5090/kjtcs.2013.46.5.346. Epub 2013 Oct 4. Korean J Thorac Cardiovasc Surg. 2013. PMID: 24175269 Free PMC article.
-
Butyrylcholinesterase as a perioperative complication marker in patients after transcatheter aortic valve implantation: a prospective observational study.BMJ Open. 2021 Jul 6;11(7):e042857. doi: 10.1136/bmjopen-2020-042857. BMJ Open. 2021. PMID: 34230011 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous